FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2884655079> ?p ?o ?g. }

• W2884655079 abstract "The expression of the immunoregulatory protein B7-H4 has been reported in many types of cancer, including breast cancer. However, its role in triple-negative breast cancer (TNBC), especially its correlation with patients' prognosis and chemoresistance remains unclear.The expression of B7-H4 in TNBC tissues and cell lines were measured with Real-Time PCR and western blotting. 65 cases of TNBC tissue samples and adjacent non-tumor tissue samples were analyzed by immunochemistry to demonstrate the correlation between the B7-H4 expression and clinicopathological characteristics. In vitro studies assessed mAb MIH43 alone and in combination with transfecting B7-H4 siRNA on the growth of chemosensitive and chemoresistant TNBC cell lines by CCK-8 and apoptotic enzyme-linked immunosorbent assay (ELISA).B7-H4 expression was detected positive in 59 of 65 (90.8%) different stage TNBC patients, especially in the samples of recurrence TNBC patients after receiving neoadjuvant chemotherapy treatment. Survival curves showed that patients with B7-H4 overexpression had significantly shorter survival and recurrence time than those with low B7-H4 expression (p < 0.005). Univariate and multivariate COX regression analysis demonstrated that B7-H4 was an independent predictor for advanced tumor stage. The monoclonal antibody of B7-H4 has the potential anti-proliferative effects on inhibiting the chemoresistant TNBC cell lines and increasing the sensitivity of TNBC cell lines to doxorubicin, paclitaxel or carboplatin. RNAi-mediated silencing of B7-H4 in TNBC cells enhanced drug-induced apoptosis via inhibiting PTEN/PI3K/AKT pathway, whereas reexpression of B7-H4 in B7-H4 knockdown and low B7-H4 expressing cells increased the phosphorylation of PI3K and AKT along with restoration of PETN expression.Our data show that B7-H4 is a biomarker indicative of a poor prognosis in TNBC patients and at least partially downregulated in chemoresistance via PTEN/PI3K/AKT pathway. Targeting B7-H4 might provide an attractive therapeutic approach specifically for TNBC patients." @default.
• W2884655079 created "2018-08-03" @default.
• W2884655079 creator A5005509944 @default.
• W2884655079 creator A5012278873 @default.
• W2884655079 creator A5050487837 @default.
• W2884655079 creator A5050665386 @default.
• W2884655079 creator A5080411122 @default.
• W2884655079 date "2018-07-13" @default.
• W2884655079 modified "2023-09-28" @default.
• W2884655079 title "B7-H4 overexpression contributes to poor prognosis and drug-resistance in triple-negative breast cancer" @default.
• W2884655079 cites W1652018515 @default.
• W2884655079 cites W1745893103 @default.
• W2884655079 cites W1781387617 @default.
• W2884655079 cites W1872541606 @default.
• W2884655079 cites W1905216491 @default.
• W2884655079 cites W1975731864 @default.
• W2884655079 cites W1992184534 @default.
• W2884655079 cites W1992324708 @default.
• W2884655079 cites W1999843687 @default.
• W2884655079 cites W2011081374 @default.
• W2884655079 cites W2018439447 @default.
• W2884655079 cites W2021951737 @default.
• W2884655079 cites W2025701875 @default.
• W2884655079 cites W2029161762 @default.
• W2884655079 cites W2033892848 @default.
• W2884655079 cites W2036852376 @default.
• W2884655079 cites W2042994628 @default.
• W2884655079 cites W2067576594 @default.
• W2884655079 cites W2075804595 @default.
• W2884655079 cites W2076308913 @default.
• W2884655079 cites W2076629535 @default.
• W2884655079 cites W2080978893 @default.
• W2884655079 cites W2086734209 @default.
• W2884655079 cites W2101338052 @default.
• W2884655079 cites W2134523831 @default.
• W2884655079 cites W2149748445 @default.
• W2884655079 cites W2152181862 @default.
• W2884655079 cites W2167339883 @default.
• W2884655079 cites W2227512256 @default.
• W2884655079 cites W2288482051 @default.
• W2884655079 cites W2308813426 @default.
• W2884655079 cites W2330212966 @default.
• W2884655079 cites W2333667452 @default.
• W2884655079 cites W2402636472 @default.
• W2884655079 cites W2411382228 @default.
• W2884655079 cites W2415521374 @default.
• W2884655079 cites W2461385029 @default.
• W2884655079 cites W2463471218 @default.
• W2884655079 cites W2464921739 @default.
• W2884655079 cites W2467321712 @default.
• W2884655079 cites W2474371759 @default.
• W2884655079 cites W2491689620 @default.
• W2884655079 cites W2519190573 @default.
• W2884655079 cites W2522277966 @default.
• W2884655079 cites W2523763608 @default.
• W2884655079 cites W2528806911 @default.
• W2884655079 cites W2530504769 @default.
• W2884655079 cites W2543049646 @default.
• W2884655079 cites W2549171991 @default.
• W2884655079 cites W2549441121 @default.
• W2884655079 cites W2550122483 @default.
• W2884655079 cites W2551065090 @default.
• W2884655079 cites W2553642601 @default.
• W2884655079 cites W2554598612 @default.
• W2884655079 cites W2556761501 @default.
• W2884655079 cites W2560725476 @default.
• W2884655079 cites W2569795452 @default.
• W2884655079 cites W2616293926 @default.
• W2884655079 cites W806321452 @default.
• W2884655079 doi "https://doi.org/10.1186/s12935-018-0597-9" @default.
• W2884655079 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6044050" @default.
• W2884655079 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30008617" @default.
• W2884655079 hasPublicationYear "2018" @default.
• W2884655079 type Work @default.
• W2884655079 sameAs 2884655079 @default.
• W2884655079 citedByCount "27" @default.
• W2884655079 countsByYear W28846550792018 @default.
• W2884655079 countsByYear W28846550792020 @default.
• W2884655079 countsByYear W28846550792021 @default.
• W2884655079 countsByYear W28846550792022 @default.
• W2884655079 countsByYear W28846550792023 @default.
• W2884655079 crossrefType "journal-article" @default.
• W2884655079 hasAuthorship W2884655079A5005509944 @default.
• W2884655079 hasAuthorship W2884655079A5012278873 @default.
• W2884655079 hasAuthorship W2884655079A5050487837 @default.
• W2884655079 hasAuthorship W2884655079A5050665386 @default.
• W2884655079 hasAuthorship W2884655079A5080411122 @default.
• W2884655079 hasBestOaLocation W28846550791 @default.
• W2884655079 hasConcept C104317684 @default.
• W2884655079 hasConcept C119056186 @default.
• W2884655079 hasConcept C121608353 @default.
• W2884655079 hasConcept C126322002 @default.
• W2884655079 hasConcept C143998085 @default.
• W2884655079 hasConcept C173396325 @default.
• W2884655079 hasConcept C190283241 @default.
• W2884655079 hasConcept C2776694085 @default.
• W2884655079 hasConcept C2777292972 @default.
• W2884655079 hasConcept C2780110267 @default.
• W2884655079 hasConcept C2781303535 @default.
• W2884655079 hasConcept C502942594 @default.

• next